Q32 Bio Inc. (QTTB)
| Market Cap | 91.06M +303.5% |
| Revenue (ttm) | 53.74M |
| Net Income | 33.24M |
| EPS | 2.59 |
| Shares Out | 16.96M |
| PE Ratio | 2.07 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 113,926 |
| Open | 5.37 |
| Previous Close | 5.44 |
| Day's Range | 5.27 - 5.47 |
| 52-Week Range | 1.35 - 8.05 |
| Beta | -1.27 |
| Analysts | Strong Buy |
| Price Target | 13.00 (+142.09%) |
| Earnings Date | May 5, 2026 |
About QTTB
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatm... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for QTTB stock is "Strong Buy" and the 12-month stock price target is $13.0.
News
Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
-- Bempikibart 36-week topline data readout from Part B of SIGNAL-AA Phase 2a clinical trial on-track for mid-2026 -- -- First patient dosed in SIGNAL-AA Part B open-label extension (OLE) -- -- Comple...
Q32 Bio Transcript: 25th Annual Needham Virtual Healthcare Conference
Bempikibart, a bifunctional antibody for alopecia areata, is in phase II with mid-year data expected. The drug targets key immune pathways and aims to address significant unmet needs with a differentiated safety and administration profile. Cash runway extends through Q4 2027.
Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference
WALTHAM, Mass., April 8, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and ot...
Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
-- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; 36-week topline data readout expected in mid-2026 -- -- Complete...
Q32 Bio Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Bempikibart is advancing in alopecia areata with promising proof-of-concept and a robust phase IIa program, aiming to address unmet needs with a safer, durable biologic. Top-line 36-week data are expected midyear, with a focus on expanding into other T-cell driven diseases.
Q32 Bio initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Q32 Bio (QTTB) with a Buy rating and $13 price target The firm says the company’s bempikibart targets an opportunity in alopecia areata where current
Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
WALTHAM, Mass., Feb. 18, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and ot...
Q32 Bio announces $10.5M registered direct offering
Q32 Bio (QTTB) announced a $10.5M registered direct offering. This transaction was led by a new institutional investor with participation by an existing dedicated public institutional investor. Q32 Bi...
Q32 Bio Announces $10.5 Million Registered Direct Offering
WALTHAM, Mass., Feb. 17, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and ot...
Why Is Q32 Bio Stock (QTTB) Up Today?
Q32 Bio stock took off on Monday after the company announced an asset sale.
Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront
Q32 Bio (QTTB) announced that it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics (AKBA). Akebia has acquired ADX-097 and will be responsible for future development and
Q32 Bio sells complement inhibitor ADX-097 to Akebia
Q32 Bio (QTTB) announced that it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics (AKBA). “This transaction strengthens our cash position through additional non-dilutive fund...
Q32 Bio Sells Complement Inhibitor ADX-097
-- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata -- -- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash ru...
Q32 Bio reports Q3 EPS (60c), consensus ($1.19)
“The third quarter was marked by strong execution across our bempikibart development program in AA, culminating in the recent completion of enrollment in Part B of our SIGNAL-AA clinical trial
Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
-- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; topline data readout expected in mid-2026 -- -- Dosing of patien...
Q32 Bio completes enrollment in Part B of SIGNAL-AA trial
Q32 Bio (QTTB) announced that it has completed enrollment in Part B of its SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe AA. Bempikibart
Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata
-- SIGNAL-AA Part B exceeded target enrollment based on demand from patients; trial size increased to 33 patients -- WALTHAM, Mass. , Oct. 21, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bi...
Q32 Bio Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
Bempikibart is advancing in phase II-B for alopecia, showing earlier and durable responses with a strong safety profile. Operational changes and a new dosing strategy are improving trial outcomes, and the company is well-funded into 2027.
Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference
WALTHAM, Mass. , Aug. 28, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and o...
Eight option delistings on August 18th
Option delistings effective August 18th include Q32 Bio Inc (QTTB), Hyperdynamics Corp (HYPD), Bionano Genomics (BNGO), Allurion Technologies Inc (ALUR), Moxian (BVI) Inc (ABTS), Spi Energy Co Ltd (SP...
Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
-- Dosing of patients in Part A open-label extension (OLE) and Part B of SIGNAL-AA ongoing; SIGNAL-AA Part B topline data readout on-track for 1H'26 -- -- Strengthened leadership team with appointment...
Q32 Bio chief medical officer Jason Campagna to depart
Q32 Bio (QTTB) announced the appointment of Adrien Sipos as interim chief medical officer. Sipos succeeds Jason Campagna who will be departing the company. Prior to joining Q32 Bio, Sipos
Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer
-- Dr. Sipos is an immunologist and seasoned Immunology and Inflammation (I&I) drug developer, with over 25 years of clinical development and medical affairs leadership experience -- WALTHAM, Mass. , ...
Oxford Biomedica completes acquisition of remaining stake in U.S. subsidiary
OXB has acquired the remaining 10% stake in its US subsidiary from Q32 Bio (QTTB), bringing its ownership, as planned, to 100%. As previously disclosed in the Company’s Preliminary Results
Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
-- First patient dosed in SIGNAL-AA Phase 2a Part B; topline data readout on-track for 1H'26 -- -- First patient dosed in SIGNAL-AA Part A open-label extension (OLE) -- -- Fast Track designation (FTD)...